No Spotlight Needed

Sheetal Prasad
  • 5.0 (12)
  • Business
  • Updated Daily

No Spotlight Needed is a leadership podcast that explores the human stories behind extraordinary executives. Through candid, in-depth conversations, CEOs and senior executives reveal the values, formative experiences, and decision-making frameworks that rarely make headlines but leave a lasting impact. These stories highlight critical lessons and management insights from today’s most effective business leaders. Whether you’re an aspiring leader, a seasoned executive, or simply curious about the intersection of character and business, this podcast offers clarity, humility, and practical wisdom

  1. 2d ago

    How Jeff Park Turned a $200M Company Into $12.8 Billion

    Jeff Park spent over a decade transforming SXC Health Solutions into Catamaran, a pharmacy benefits technology company that sold to UnitedHealthcare for $12.8 billion, a 65 times return on the original investment. He did it through 14 plus acquisitions, a relentless integration playbook, and one core belief: people are the only competitive advantage. In this episode of No Spotlight Needed, Jeff walks through how he earned the right to speak as a 25 year old sitting on ten boards, what the IPO taught him about investor storytelling, how to compete with your own customers and win, the three filters behind every M&A decision, why culture kills deals and how they stopped it, and what a year and a half in Portugal taught him about what actually matters. Let's connect:LinkedIn: / sheetal-mehta-prasadOur Website: https://www.nospotlightneeded.comSubscribe to the Channel: / @nospotlightneeded Timestamps: 1:27 - Introduction: Jeff Park and the SXC to Catamaran story2:33 - Welcome and what Waltz Health does3:09 - One drug, 2200 different prices: the problem Waltz is solving4:27 - 14 million lives, $300 million saved: what it looks like in practice5:25 - Starting in venture capital at Covington Capital in his 20s6:31 - Sitting on ten boards as a 25 year old: what he actually contributed8:17 - How to earn the right to speak when you are the youngest in the room9:14 - The leverage equation: diligence before the check, none after9:55 - Making the leap from investor to operator as CFO of SXC10:51 - What he thought the job would look like versus what it actually was11:09 - IPO lessons: who tells your story after the roadshow matters more than the bank name12:03 - Why JPMorgan was the wrong choice for a $200M market cap company12:20 - The Cory Tobin lesson: it is okay to say I do not know13:45 - The post-it note Jeff carried on every earnings call for ten years14:59 - At what point did they decide to become a PBM and compete with their own customers?15:23 - The Formula One car in the lobby and the moment everything changed16:44 - The first acquisition: NMC in 2008 for $143 million, all chips in17:47 - Competing with clients: the pathway to control as the kill shot19:52 - The M&A playbook: the three filters for every deal20:52 - Why people retention is the real integration risk21:13 - Tripling the EBITDA on NMC and turning skeptics into believers21:39 - The integration playbook: one answer, one process, one platform22:03 - Friday morning executive standups that ran for ten years23:37 - How they knew the organization was ready for the next deal24:54 - NMC to Catalyst: a $143M deal followed by a $4.4B deal25:38 - The culture problem inside Catalyst: Sox fans and Cubs fans26:57 - Changing the company name entirely and why it mattered27:40 - Day one actions: the 90 day window that defines integration success28:01 - Building a combined leadership team from both sides29:39 - Selling to UnitedHealthcare for $12.8 billion30:03 - What Jeff loved about United and why he still left after a year31:02 - At 45 with kids aged 10 and 13, the decision to move to Portugal34:02 - What you realize when you are never fully present anywhere35:38 - A year and a half of reflection: how do I define myself when I am not working?36:10 - Three things he decided he wanted from every chapter going forward37:34 - The Welldyne opportunity: chairman and CEO, Carlyle backed, rinse and repeat39:03 - Recruiting 40 former employees and building again from scratch39:36 - If you are not buying you are dying: the PBM reality41:01 - The FTC investigation and the real problem with PBM scale42:00 - $600 billion in drug spend, $100 billion paid by patients, 100 million abandoned prescriptions43:18 - What regulation actually creates: the conditions for disruption44:16 - The Jeff and Mark dynamic: what makes a 20 year partnership work45:32 - Joining Waltz Health: the right people, the right problem, the right moment

    54 min

  2. Jun 26

    This CEO Thinks Like a Chess Player: Building a $400M Biotech from Scratch

    Some of the best conversations are with the people you think you already know. In this episode of No Spotlight Needed, host Sheetal Mehta Prasad sits down with Dipal Doshi, CEO of Entrada Therapeutics, for an honest look at what it takes to build a biotech company with conviction. Dipal was Entrada's first full-time employee. As a non-scientist, he helped take the company from an unproven hypothesis through its IPO and into active clinical development in one of the most competitive areas in biotech: Duchenne muscular dystrophy. What comes through is how intentional he is. He thinks like a chess player, always looking three or four moves ahead, and he blocks off every Friday just to keep asking the right questions. Sheetal and Dipal get into Entrada's founding story, the winding career path that led him there, what it really takes to raise capital for an early stage company, leading through a clinical hold, the patient first culture his team has built, and how he stays grounded at home. His view on the industry says a lot: biotech is not a high failure business, it is a high hope one. This conversation was recorded before Entrada's recent clinical data release. The leadership lessons are still very relevant, and the company's mission has not changed. Let’s connect: LinkedIn: https://www.linkedin.com/in/sheetal-mehta-prasad/ Our Website: https://www.nospotlightneeded.com/ Subscribe to the Channel: https://www.youtube.com/@NoSpotlightNeeded/subscribe  Timestamps: 0:00 Cold open 2:09 Welcome to the show 2:13 A pivot that was not forced 2:48 Why he blocks off every Friday 4:39 Stewards of capital and careers 5:13 A liberal arts kid with a five year plan 6:25 What sales really teaches you 7:14 Consulting, then Eli Lilly and a North Star 8:21 Wharton, banking, and the capital markets 9:52 Raising 400 million dollars 12:20 The bet: proving you can get inside the cell 14:02 The Amicus years and John Crowley 17:50 Biotech is not high failure, it is high hope 19:12 How Entrada found him 22:49 The lunch that started a partnership 25:08 Going public during Covid 26:53 Living through a clinical hold 31:03 Building a culture people can feel 34:23 Patients on the wall 35:55 Cutting through the noise in DMD 38:14 The obligation to obsolete your own technology 39:29 Staying present at home 40:52 The loneliest job 43:28 Losing his father, and his mother's strength 45:19 Keep your North Star

    46 min

  3. Jun 19

    The AI Company Nobody Believed In | Jurgi Camblong Interview

    On paper, SOPHiA GENETICS should not have worked. Jurgi Camblong was not a software engineer or a trained CEO. He was building an AI company in Switzerland in 2011 before AI was a mainstream conversation, raising capital in Europe when most of the money was in the United States, and selling to hospitals that needed years to trust the technology. Fifteen years later, SOPHiA GENETICS supports nearly 1000 hospital customers and has analyzed over 2.5 million genomic profiles. In this conversation, Jurgi talks about growing up in the Basque region of France, overcoming severe dyslexia, putting his entire life savings into a ten square meter room with a leaking espresso machine, and what it actually took to build a company when every structural advantage was working against you. Let's connect:LinkedIn: / sheetal-mehta-prasadOur Website: https://www.nospotlightneeded.comSubscribe to the Channel: / @nospotlightneeded Timestamps: 0:00 - Teaser: life savings, virtues vs values, alone you go faster0:57 - Introduction: Jurgi Camblong and the SOPHiA GENETICS story2:39 - Why the lowercase i in SOPHiA stands for artificial intelligence3:09 - Founded in 2011 with no technology, just a dream and a vision4:13 - Is SOPHiA GENETICS a tech company or a healthcare company?5:16 - Releasing software updates every three weeks like a true tech company6:32 - 100% digital from day one6:55 - Growing up in the Basque region of France: roots that defined everything8:05 - Parents building their own schools on weekends to preserve the language9:43 - Learning English at 30 surrounded by researchers in Geneva11:12 - Overcoming severe dyslexia: writing witch as w-i-t-c-h in a PhD presentation12:27 - Faking injuries to avoid spelling tests as a child13:00 - How dyslexia became a gift: obsession with details and knowing the answer15:21 - The founding story: meeting Pierre Hutter and Lars Steinmetz16:05 - Starting in a ten square meter room with a leaking espresso machine16:59 - The vision: hospitals learning from each other through a collective data platform18:06 - Splitting roles with the founders in the early days18:37 - Starting the MBA the same week as the company with two young kids at home20:14 - Why the MBA was not transformative but deeply reassuring21:29 - Why it took three years to build the first product customers could use23:37 - Door to door sales: convincing hospitals to trust cloud and AI24:51 - The early crisis: customers paid but never used the platform25:14 - The whiteboard moment that became SOPHiA GENETICS customer onboarding methodology27:07 - Raising $250 million as a European company when most funding was in the US28:22 - Putting $70,000 of life savings in. Then the investor backed out and his wife lost her job.31:01 - Why going public was never just about the money33:03 - IPO at $18. Stock dropped 80% while revenue grew 40%.33:30 - The message to employees: the stock is not the metric, patients are35:10 - Values are about beliefs. Virtues are about actions.35:51 - The SOPHiA GENETICS virtues: we do, we decide, we learn, we adapt, we innovate, we collaborate36:19 - The scaling challenge: moving from people to process between 300 and 500 employees38:07 - The post-Covid overhiring mistake and what it cost the company39:32 - How the company came out stronger and better after digesting it40:14 - Why communication clarity is a completely different skill at 500 people41:17 - Partnerships: from Multiplicom to AstraZeneca to Memorial Sloan Kettering43:06 - Up against all odds: why did SOPHiA GENETICS actually work?44:18 - Digital twins: what Jurgi is building toward in his next chapter47:11 - Stepping down as CEO on his own terms and handing to an internal successor49:25 - What he will focus on next: external affairs, advocacy, and innovation

    54 min

  4. Jun 12

    The Quiet Leader Who Built a $130B Health Company

    Paul Perreault led CSL for a decade, growing it into a $130 billion market cap company and the world's leading manufacturer of plasma derived therapies. He started as a field sales rep, planned to become a priest, and carried one lesson through his entire career: never confuse your job title with who you are. In this conversation Paul talks about the generalist philosophy that shaped his leadership, the capital discipline that made CSL different from every other biotech, the three major acquisitions that defined his tenure including the one that did not play out as expected, what it was like navigating Covid as a company deep in plasma collection and vaccine manufacturing, and when he knew it was time to leave a company before complacency set in. Direct, patient, and completely uninterested in the spotlight. Let's connect: LinkedIn: / sheetal-mehta-prasad Our Website: https://www.nospotlightneeded.com Subscribe to the Channel: / @nospotlightneeded Timestamps: 0:00 - Teaser: never confuse your job with who you are 0:50 - Introduction: Paul Perreault and CSL 2:10 - The Detour CEO: what detour means in a career 3:54 - The seminary: why the structure forced him to leave 6:08 - You can be CEO of the largest company and still take out the trash 6:39 - Growing up the second of eight kids and what it taught him 7:23 - Starting as a field rep and planning to retire as one 8:09 - The value of being a generalist in a world that rewards specialists 9:27 - The Wharton simulation: why diverse teams build better businesses 12:46 - His father worked at the same company: what he learned from him 13:52 - When is the right time to leave? The complacency signal 15:33 - Once you hit the peak it is all downhill 16:09 - Joining Centeon: the leap from a large company to a small one 16:31 - Why the plasma business is completely different from pharma and biotech 18:31 - 200 days from collection to product on the market 19:19 - Why CSL required extreme capital discipline that pharma never does 20:36 - Becoming CEO in 2013 and the decision to accelerate plasma center growth 21:08 - What immune deficiency actually looks like for patients 24:07 - Growing plasma centers: the demand was always there, the supply was not 27:20 - The flu vaccine acquisition: everybody said he was crazy 30:57 - They all said I was crazy. Less than five years later: $1B in revenue and 20% EBITDA. 32:09 - The gene therapy deal: why he waited until 2020 to enter the space 33:46 - Why he went after hemophilia B when everyone else chased hemophilia A 35:31 - There is a lot of money in a cure: the economics of the $3.5M treatment 36:39 - The scoreboard was never the game plan 37:09 - The $11.7B Vifor acquisition: the deal that did not go as expected 38:30 - The opportunity was right. Maybe the price was not. 42:43 - Nobody from the company had ever visited the plants. He showed up anyway. 44:16 - We were not serial acquirers. Three deals in ten years. 45:08 - Covid: screaming for a vaccine, then criticizing it when side effects emerged 46:42 - The product was not rushed. The funding just moved faster. 47:30 - Getting three competitors together to collect convalescent plasma 49:09 - Feeling helpless in Switzerland while his teams showed up every day 51:10 - Covid was the macro example of something leaders face every single day 52:39 - Sustaining mental, physical, business, and family health all at once 52:53 - Closing reflections

    53 min

  5. May 29

    How This Company Went From Nothing To $4 Billion!

    Kevin Sayer spent 15 years as CEO of Dexcom, growing it from a niche startup into a $4 billion company that created the continuous glucose monitoring industry from scratch. In this episode of No Spotlight Needed, he sits down with Sheetal to tell the whole story: the early bets, the hard lessons, the bold moves, and what it really took to build something that has saved lives around the world. Kevin opens up about his recent cancer diagnosis and recovery, the toughest quarter of his career in 2024, why he delayed the G4 launch and tanked the stock price, the Super Bowl ad decision, the Google partnership, how Dexcom responded to the GLP-1 threat, and why he stepped down on his own terms. This is a masterclass in long-term thinking, accountability, and building a business you believe in. Let's connect: LinkedIn: / sheetal-mehta-prasad Our Website: https://www.nospotlightneeded.com Subscribe to the Channel: / @nospotlightneededTimestamps: 0:00 - Teaser 0:53 - Introducing Kevin Sayer 2:30 - Cancer diagnosis and recovery 3:34 - The hardest quarter: 2024 4:33 - Accountability, no excuses 7:10 - Meeting the commercial team every day 7:38 - Identifying who your customer really is 10:02 - Growing up in Idaho: the Jeep dealership 11:04 - Never judge anyone by what they're wearing 12:28 - Driving car lots at night: customer retention 13:40 - CFO of Mini Med under Alfred Mann 14:07 - He lied about the $10M raise 15:16 - What Alfred Mann taught him: tenacity 16:09 - Someone gave us a chance we didn't deserve 16:27 - Hospital bed visit: implantable pump under the covers 17:37 - Mini Med acquired by Medtronic for $3.5B 19:58 - Never run a business to sell it 21:33 - Specialty Labs, Biosensors, the years in between 22:18 - His wife: most unhappy I've ever seen you 23:10 - Nobody offered him an operating role 25:14 - Joining Terry Gregg and moving to San Diego 26:11 - Terry's recruiting lesson: how do you want to do this? 27:22 - What made Terry Gregg a remarkable leader 30:35 - G4: first decision drove the stock from 17 to 6 31:36 - Not good enough, and they know how to fix it 32:19 - Daily engineer meetings and the October 15th deadline 33:04 - Why G4 was the pivotal moment 35:04 - Scaling from $76M to $600M 35:38 - Technology first, then commercial, then manufacturing 38:27 - Going to the phone and data sharing 40:35 - The email from the law student in Topeka 44:29 - The Super Bowl ad debate: $5.5M for 30 seconds 44:55 - His father's last call before he passed 46:52 - Text from UnitedHealthcare: this is very cool 48:00 - Second Super Bowl ad for G7: $7M 48:42 - Stelo and going direct to consumer 49:08 - The Google partnership 51:00 - Partnerships are not marriages 51:54 - Embracing GLP-1s instead of fearing them 55:32 - Stepping down before anyone pushed him out 55:54 - Most proud of: creating an industry from scratch

    57 min

  6. May 22

    Perfect Chemistry: The Untold Story Behind the Hepatitis C Cure

    What does a career look like when one chapter ends with an $11 billion acquisition, the next involves FBI visits and death threats, and the third ends with a devastating phase 3 failure that nobody saw coming?Dr. Michelle Berrey has lived all three. Over 15 years as a chief medical officer and CEO at Pharmasset, Chimerix, and Intercept Pharmaceuticals, she helped develop a cure for hepatitis C, navigated a national social media firestorm over a dying child, led a company through the Ebola outbreak, and faced a phase 3 failure that dropped the stock 90% overnight.In this conversation, she talks through every chapter with rare honesty, including what it takes to build a career-long relationship with the FDA, how she became CEO in 48 hours without asking for the job, and why the most important thing she ever learned was not to define yourself by your most recent result.Let's connect:LinkedIn: / sheetal-mehta-prasad Our Website: https://www.nospotlightneeded.com Subscribe to the Channel: / @nospotlightneededTimestamps:0:00 - Teaser: death threats, the FBI, an $11B deal, and a 90% stock drop0:39 - Introduction: Dr. Michelle Berrey and her three biotech chapters2:26 - Three very different chapters: what have you learned?3:08 - Why Big Pharma drove her nuts and biotech set her free4:04 - Fail fast and focus: the operating philosophy that defined her career5:37 - Training during the HIV crisis at University of Washington6:12 - Standing outside bathhouses to understand transmission7:03 - Running her first clinical trials and learning to pay attention to outliers7:47 - Moving to GSK and using it like a university10:01 - Raising two kids as a single mom while building a career at Glaxo11:37 - The decision to leave Big Pharma for something more entrepreneurial12:43 - Joining Pharmasset as CMO: no committees, never looked back13:27 - The Hepatitis B phase three and the safety signal from Korea15:05 - Patient safety above everything: pivoting to Hep C16:44 - From the very first three patients, the viral load just kept dropping17:39 - The interferon question and why they went to New Zealand20:58 - Gilead approaches with an $11 billion offer at a 90% premium21:28 - Did you want to sell? "I didn't. It was my baby."22:23 - "It warms my heart every time I meet someone whose life was changed"22:36 - What made Pharmasset almost perfect: the chemistry and the prodrug23:41 - A fairytale ending on two fronts: the acquisition and a love story29:41 - The Josh Hardy story: a sick child and 80,000 tweets31:17 - "We had the FBI come in. We were getting death threats. The drug worked."32:02 - Named CEO in 48 hours: a field promotion she never asked for33:43 - The team that made the CEO role work35:49 - Six months later: Ebola and 2am calls with the FDA37:22 - A career-long relationship with the FDA built on trust and urgency39:09 - The SUPPRESS trial: December 15, 2015. Did not hit statistical significance.39:37 - Worse outcomes in the drug arm. "What does statistics matter when you're talking about lives."40:03 - Weeks of around the clock analysis: a protocol issue, not the drug40:36 - Stock falls 90%. A third of employees let go.42:12 - "The drug is not you"43:05 - Joining Intercept: a second FDA rejection already on the books44:16 - The complexity of liver biopsy endpoints compared to viral load45:42 - The advisory committee: "The odds were not in our favor"46:34 - Intercept sold to Alfasigma. Michelle steps away.47:46 - Advice to biotech teams: believe in your drug, stress test it, find the outliers50:19 - Is she done? "Richard thinks it's a sabbatical"50:54 - Mentoring young women in science51:46 - Closing reflections: when one door closes, another opportunity finds you

    53 min

  7. May 15

    What $12 Billion in Biotech Exits Taught This CEO About Relationships, Risk, and Near-Death

    What does it actually take to build a biotech from nothing... no IP, no programs, no money — into a company acquired by Eli Lilly for over $3 billion? In this episode of No Spotlight Needed, host Sheetal sits down with Praveen Tipirneni — engineer, physician, and military-trained biotech CEO who built Morphic Therapeutic over nine years, nearly died from an out-of-hospital cardiac arrest midway through, and still came back to close one of biotech's biggest deals of 2024. Now he's doing it again with Caldera Therapeutics. What we cover: - Why he sold before Phase 2B data — and the real math behind that call - Walking into his second board meeting ready to blow up the portfolio and get fired - Why people invest in people, not science — and the relationships that built every round - His no-PowerPoint writing culture (yes, before Bezos) - Why slowing down was always his instinct — and why it worked - The Friday the stock dropped 30% and the cardiac arrest that followed - His honest skepticism about AI in drug discovery - What drew him back to build Caldera Let’s connect: LinkedIn: https://www.linkedin.com/in/sheetal-mehta-prasad/ Our Website: https://www.nospotlightneeded.com/ Connect with Praveen: https://www.linkedin.com/in/praveen-tipirneni-42a1a5/ Subscribe to the Channel: https://www.youtube.com/@NoSpotlightNeeded/subscribe Timestamps: 0:00 - Teaser: almost dying, relationships, and the stock drop Friday 0:40 - Intro: Praveen Tipirneni and the $3B Lilly acquisition 2:13 - Why sell Morphic before Phase 2B data? 3:06 - IBD isn't a disease a small company can commercialize 3:58 - The Olympics ad break analogy 5:41 - Not wanting to be CEO at 45 6:46 - The mentor who said "this is your window"8:26 - First six months at Morphic: sensing something was wrong 9:24 - "I don't just dislike our portfolio — I hate it" 10:47 - Starting from scratch: no IP, no programs, no money 13:13 - Why raising capital is all about relationships 14:26 - "Any biotech is a leap of faith. People invest in people." 15:02 - The Nils story: said no at Series A, led Series B 15:40 - Rajiv at Fidelity and how that relationship made the IPO 16:19 - The mistake: only calling investors when you're raising 17:13 - Morphic's use of Schrödinger and computational chemistry 19:39 - Why Praveen is an AI skeptic in drug discovery 21:50 - Building Morphic's culture: serious, deliberate, written 23:03 - The no-PowerPoint philosophy — before Bezos 25:28 - Tech vs. biotech: why "move fast" doesn't work here 28:22 - Being a conservative CEO — raising less than he could 29:02 - Letting people own their domains: the CFO story 33:25 - The cardiac arrest: stock drop, investor calls, and then nothing 35:30 - Two more arrests by Tuesday. Doctors said he wouldn't survive. 37:20 - "I should have died that day. Every day is not guaranteed." 38:47 - Why hiring great people meant the company ran without him 40:07 - The "break" that didn't last — and what pulled him back in 41:46 - Why he hired no one he knew for the first 2-3 years 43:21 - Cubist: joining a company at negative enterprise value 45:40 - What failures can you point to? 47:58 - CEO vs. Chairman: why they should always be separate 49:04 - Advice to founders: "It's never about the data" 50:46 - Life at Caldera: team-building, wearing every hat 53:18 - IPO as competitive moat and branding event 54:30 - Is biotech a race? What China has changed 54:48 - Free time: racing up mountains and everyone telling him to act his age 55:36 - Closing reflections

    55 min

  8. May 1

    Former CEO Explains How to Build a Forever Company With Culture That STICKS!

    Welcome to Season 2 of No Spotlight Needed! Episode 1 features Bruce Cozadd, former CEO of Jazz Pharmaceuticals. Bruce walks through the real moments behind building Jazz into a durable business, including what happened during the 2008 crash, how he thought about culture as the company scaled, why “bet the company” decisions need to be named out loud, and what it looks like to step away after a 20 plus year run without leaving a shadow behind. If you care about leadership, team building, and making hard calls with clarity, this one is a masterclass. What you’ll hear in this episode - What crisis leadership actually requires when people are scared - The “plan B, plan C, plan D” mindset that helped Jazz survive - A culture system that gives real signal, not lip service - When founders stay involved and when it hurts the new CEO - How to run succession without creating chaos Let’s connect:LinkedIn: https://www.linkedin.com/in/sheetal-mehta-prasad/ Our Website: https://www.nospotlightneeded.com/Subscribe to the Channel: https://www.youtube.com/@NoSpotlightNeeded/subscribe Timestamps: 0:00 Intro: why Jazz is “quietly different” 01:45 Building Jazz to create value without selling 04:49 Culture: defining it and making it measurable 06:06 Breakfast with Bruce: using new hires to gauge culture 08:02 Culture signals that actually matter (not slogans) 11:44 Founder staying involved: when it helps vs hurts 14:03 The danger of the old CEO “looking over your shoulder” 22:53 Going public: pros, cons, and ignoring the ticker 26:15 The 2008 to 2009 moment that almost ended Jazz 29:05 “Bet the company” decisions: name it out loud 30:14 Survival mode: cutting burn and reducing headcount 31:30 Mission and leadership: clarity, integrity, trust 41:09 Diversifying beyond one product: the long game 43:46 Measuring culture: surveys plus real employee comments 50:38 GW acquisition: criticism, conviction, and why it mattered 52:58 Retirement: how succession should work (without chaos)

    1h 4m
See All (14)

Trailer

Ratings & Reviews

5
out of 5
12 Ratings

About

No Spotlight Needed is a leadership podcast that explores the human stories behind extraordinary executives. Through candid, in-depth conversations, CEOs and senior executives reveal the values, formative experiences, and decision-making frameworks that rarely make headlines but leave a lasting impact. These stories highlight critical lessons and management insights from today’s most effective business leaders. Whether you’re an aspiring leader, a seasoned executive, or simply curious about the intersection of character and business, this podcast offers clarity, humility, and practical wisdom

Information

  • Creator
    Sheetal Prasad
  • Years Active
    2K
  • Episodes
    14
  • Rating
    Clean
  • Copyright
    © Sheetal Prasad
  • Show Website
    No Spotlight Needed

You Might Also Like